Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
FOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on January 16, 2024, it received a notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”), because the closing bid price of the Company’s Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), was below $1.00 per share for 30 consecutive business days.
Related news for (APLM)
- Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
- 24/7 Market News Snapshot 31 March, 2025 – Apollomics Inc. Class A Ordinary Shares (NASDAQ:APLM)
- Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
- Apollomics and LaunXP Team Up to Supercharge Vebreltinib in Asia’s NSCLC Fight
- Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia